» Articles » PMID: 32656501

Clinical Trials in the Pandemic Age: What is Fit for Purpose?

Overview
Journal Gates Open Res
Date 2020 Jul 14
PMID 32656501
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

It is critical to ensure that COVID-19 studies provide clear and timely answers to the scientific questions that will guide us to scalable solutions for all global regions. Significant challenges in operationalizing trials include public policies for managing the pandemic, public health and clinical capacity, travel and migration, and availability of tests and infrastructure. These factors lead to spikes and troughs in patient count by location, disrupting the ability to predict when or if a trial will reach recruitment goals. The focus must also be on understanding how to provide equitable access to these interventions ensuring that interventions reach those who need them the most, be it patients in low resource settings or vulnerable groups.  We introduce a website to be used by The Bill & Melinda Gates Foundation, Wellcome Trust, and other funders of the COVID Therapeutics Accelerator that accept proposals for future clinical research. The portal enables evaluations of clinical study applications that focus on study qualities most likely to lead to informative outcomes and completed studies.

Citing Articles

Scientific review of protocols to enhance informativeness of global health clinical trials.

Burford B, Norman T, Dolley S Trials. 2025; 26(1):85.

PMID: 40075544 PMC: 11899556. DOI: 10.1186/s13063-025-08763-4.


A maturity model for the scientific review of clinical trial designs and their informativeness.

Dolley S, Norman T, McNair D, Hartman D Trials. 2024; 25(1):271.

PMID: 38641848 PMC: 11027356. DOI: 10.1186/s13063-024-08099-5.


Unsupervised home spirometry supervised clinic spirometry for respiratory disease: a systematic methodology review and meta-analysis.

Anand R, McLeese R, Busby J, Stewart J, Clarke M, Man W Eur Respir Rev. 2023; 32(169).

PMID: 37673426 PMC: 10481332. DOI: 10.1183/16000617.0248-2022.


Model-informed drug repurposing: A pharmacometric approach to novel pathogen preparedness, response and retrospection.

Dodds M, Xiong Y, Mouksassi S, Kirkpatrick C, Hui K, Doyle E Br J Clin Pharmacol. 2021; 87(9):3388-3397.

PMID: 33534138 PMC: 8013376. DOI: 10.1111/bcp.14760.


Extending the OMOP Common Data Model and Standardized Vocabularies to Support Observational Cancer Research.

Belenkaya R, Gurley M, Golozar A, Dymshyts D, Miller R, Williams A JCO Clin Cancer Inform. 2021; 5:12-20.

PMID: 33411620 PMC: 8140810. DOI: 10.1200/CCI.20.00079.

References
1.
Dowden H, Munro J . Trends in clinical success rates and therapeutic focus. Nat Rev Drug Discov. 2019; 18(7):495-496. DOI: 10.1038/d41573-019-00074-z. View

2.
Rosala-Hallas A, Bhangu A, Blazeby J, Bowman L, Clarke M, Lang T . Global health trials methodological research agenda: results from a priority setting exercise. Trials. 2018; 19(1):48. PMC: 5798175. DOI: 10.1186/s13063-018-2440-y. View

3.
Zhao Y, Wei Y, Shen S, Zhang M, Chen F . Appealing for efficient, well organized clinical trials on COVID-19. Ann Transl Med. 2020; 8(10):632. PMC: 7290614. DOI: 10.21037/atm-20-2429. View

4.
Blagden S, Billingham L, Brown L, Buckland S, Cooper A, Ellis S . Effective delivery of Complex Innovative Design (CID) cancer trials-A consensus statement. Br J Cancer. 2020; 122(4):473-482. PMC: 7028941. DOI: 10.1038/s41416-019-0653-9. View

5.
Tatsioni A, Karassa F, Goodman S, Zarin D, Fanelli D, Ioannidis J . Lost Evidence From Registered Large Long-Unpublished Randomized Controlled Trials: A Survey. Ann Intern Med. 2019; 171(4):300-301. DOI: 10.7326/M19-0440. View